December 2, 2025 4:47pm

Sector stays sour as indexes rebound

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision

It’s not always time to buy or sell; but it is time to KNOW and why!

Never leave an investor uninformed!  

News: Arrowhead Pharmaceuticals (ARWR +$1.70 or +3.02% to $57.95) receives FDA Breakthrough Therapy Designation for Plozasiran in severe Hypertriglyceridemia

Tuesday’s RMi Pre-opening Bell: Out from under or … https://www.regmedinvestors.com/articles/14213   

The peril facing the cell and gene therapy (C&GT) sector’s share pricing isn’t just applications of macro or even micro econs, sentiment or algorithms within electronic trading; it’s losing highly reliable, accurate and transparent data.

 

Tuesday: The Dow closed UP +185.13 points or +0.39%, the S&P closed UP +16.74 points or +0.25% while the Nasdaq closed UP +137.752 points or +0.59%

  • Theme of the session: indexes rebound as C&GT sector stays sour

Tuesday’s (my) 40-company covered sector’s advance/decline line opened negative with 17 incliners, 19 decliners and 4 flats ending with a negative close of 10 incliners, 29 decliners and 1 flat

  • Indexes only “seemed” to have shaken-off the risk-off sentiment that dominated Monday

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • Traders are currently optimistic that the Fed will announce an interest rate cut on Dec. 10 at conclusion of its next policy meeting. Markets have priced an 89% chance of a cut

The C&GT sector closed negative again while the CBOE Fear (VIX) index closed at 16.57 after Monday’s 17.34, Friday’s 16.35, Thursday’s holiday, Wednesday’s 17.15, and last Tuesday’s 18.56.  Metrics:  Tuesday …

  • The RUT was down -4.15 points or -0.17%,
  • The XLV was down -0.93 points or -0.60%,
  • The NBI was down -38.24 points or -0.67%;
  • The XBI was down -1.38 points or -1.15%
  • The IWM was down -0.49 or -0.20%;
  • The IBB was down -0.89 points or -0.52%,
  • The VIX was down -0.67 points or -3.88% at to 16.57

 

Q4 – December – 2 negative closes

  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 10) +$ after Monday’s

  • Alnylam Pharmaceuticals (ALNY +$10.37 after Monday’s +$3.33),
  • Vertex (VRTX +$7.55 after Monday’s -$8.01),
  • Arrowhead Pharma (ARWR +$1.70 after Monday’s +$3.55),
  • Sarepta Therapeutics (SRPT +$0.75 after Monday’s -$1.62),
  • Ultragenyx Pharmaceuticals (RARE +$0.10 after Monday’s -$1.38),
  • MiMedx (MDXG +$0.05),
  • Cellectis SA (CLLS +$0.04),
  • Brainstorm Cell Therapeutics (BCLI +$0.0210),
  • Sangamo Therapeutics (SGMO +$0.0148)

Flat (1)

  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Monday’s +$0.16 with 53 shares),

Tuesday’s Closing DOWN (10 of 29): -$ after Monday’s

  • Lenz Therapeutics (LENZ -$3.09),
  • IQVIA Holdings (IQV -$2.81 after Monday’s -$1.52),
  • BioNTech (BNTX -$1.28 after Monday’s -$5.76),
  • uniQure NV (QURE -$1.25),
  • Vericel (VCEL -$1.17 after Monday’s -$1.43),
  • AxoGen (AXGN -$0.84),
  • Ionis Therapeutics (IONS -$0.68),
  • Beam Therapeutics (BEAM -$0.68 after Monday’s -$1.28),
  • CRISPR Therapeutics (CRSP -$0.59 after Monday’s -$1.30),
  • Supernus Therapeutics (SUPN -$0.58)

 

The Bottom Line: More of the … WHYs

Indexes and many equities got “whipped” again on Tuesday after Monday’s dive.

A question does NOT answer an inquiry; investors need more than a few catalysts that could revive a rally, I do NOT expect end end-of-year flurry!

  • Depleted market valuations and the uncertain payoff from heavy spending as we get closer to 2025 ends and then coming Q4 and FY25 financial and achievement results

 

This 1st week of December:

  • 12/2 - Tuesday closed negative with 10 positive, 29 negative and 1 flat
  • 12/1 – Monday closed negative with 5 positive, 31 negative and 0 flat

Last week, November:

  • 11/28 - Friday closed positive with 29 positive, 10 negative and 1 flat
  • 11/27 – Thursday, a market holiday
  • 11/26 – Wednesday closed positive with 28 positive, 12 negative and 0 flat
  • 11/25 – Tuesday closed positive with 24 positive, 15 negative and 1 flat
  • 11/24 - Monday closed positive with 25 positive, 14 negative and 1 flat

Focus is still on the Fed's path for interest rates, even as over 85% of bets ride on a quarter-point reduction at policymakers' meeting next week.  A week that will be ...

  • September's long-delayed Personal Consumption Expenditures Price Index reading drops Friday. This is the Federal Reserve's favorite inflation gauge.
  • Labor data remains key, and the ADP private jobs report is due Wednesday followed by weekly jobless claims Thursday.

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

A real question, are cell and gene therapy (C&GT) sector companies with high insider ownership present … opportunity?

  • Do they often demonstrate alignment between management and shareholder interests … a critical factor in navigating volatile market conditions?
  • I will be looking into this …! Stay tuned.

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • “I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:   

  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Arrowhead Pharma (ARWR)
  • Monday: Capricor Therapeutics (CAPR) and Adverum Biotechnologies (ADVM)
  • Friday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Ultragenyx Pharmaceuticals (RARE)

The worst three (3) in the session:

  • Tuesday: Lenz Therapeutics (LENZ), IQVIA Holdings (IQV) and BioNTech (BNTX)
  • Monday: Vertex (VRTX), BioNTech (BNTX) and Moderna (MRNA)
  • Friday: Arrowhead Pharma (ARWR), IQVIA Holdings (IQV) and Supernus Therapeutics (SUPN)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.